News about "Eli Lilly and Company "

Eli Lilly Reports Biomarker Changes With Taltz-Zepbound Combination

Eli Lilly has reported broader immune, inflammatory and metabolic biomarker changes with Taltz and Zepbound compared with Taltz alone in the TOGETHER-PsO trial.

Eli Lilly And Company | 12/10/2026 | By News Bureau |  166

Eli Lilly India, Fortis Healthcare Mark World Alzheimer's Day

li Lilly India and Fortis Healthcare marked World Alzheimer’s Day by highlighting brain health, early signs of cognitive changes and timely medical guidance.

Eli Lilly And Company | 22/09/2026 | By News Bureau

Eli Lilly to Acquire Merida Biosciences in Deal Valued at Up to USD 2.875 Billion

Eli Lilly will acquire Merida Biosciences for up to $2.875 billion to advance precision therapies targeting disease-causing autoantibodies.

Eli Lilly And Company | 01/09/2026 | By News Bureau |  118

US FDA Grants Breakthrough Therapy Designation to Lilly's Olomorasib for Advanced Pancreatic Cancer

The US FDA has granted Breakthrough Therapy designation to Eli Lilly's investigational KRAS G12C inhibitor, olomorasib, for treating previously treated advanced pancreatic cancer, reinforcing its potential across difficult-to-treat KRAS-driven cancers.

Eli Lilly And Company | 04/08/2026 | By News Bureau |  104

BioArctic and Lilly Sign Collaboration and Research Agreement for BrainTransporter-Based Therapy

BioArctic and Lilly have entered a research and collaboration agreement to combine a Lilly compound with BioArctic’s BrainTransporter technology. BioArctic will receive a USD 30 million upfront payment under the deal.

Eli Lilly And Company | 24/06/2026 | By News Bureau |  108

Lilly's Oral GLP-1 Foundayo Shows Superior A1C Control and Weight Loss in Type 2 Diabetes

Lilly’s oral GLP-1 drug Foundayo (orforglipron) delivered superior A1C control and weight loss in 3 pivotal Type 2 Diabetes (T2D) trials, outperforming oral semaglutide and helping more patients achieve glycemic targets.

Eli Lilly And Company | 10/06/2026 | By News Bureau |  164

Eli Lilly and Company Launches Lormalzi for Early-Stage Alzheimer's Treatment in India

Eli Lilly and Company India has launched Lormalzi, a once-monthly amyloid-targeting therapy approved for early-stage Alzheimer’s disease, marking a significant advancement in evidence-based treatment options for cognitive decline in India.

Eli Lilly And Company | 14/05/2026 | By News Bureau |  167

Roche Receives CE Mark for Blood-Based Alzheimer's Diagnostic Test

Roche receives CE Mark approval for Elecsys pTau217, a blood-based Alzheimer’s diagnostic test developed with Eli Lilly, aimed at enabling earlier and less invasive detection of amyloid pathology in patients with cognitive decline.

Eli Lilly And Company | 13/05/2026 | By News Bureau |  117

Eli Lilly's Foundayo and Lower-Dose Zepbound Maintain Weight Loss in Late-Phase Trials

Eli Lilly and Company reports late-stage trial data showing Foundayo and lower-dose Zepbound helped patients maintain significant long-term weight loss after switching from higher-dose incretin therapies.

Eli Lilly And Company | 13/05/2026 | By News Bureau |  196

Eli Lilly and Company's Omvoh Shows 4-Year Disease Clearance in Ulcerative Colitis

Eli Lilly and Company’s Omvoh (mirikizumab-mrkz), the first IL-23p19 inhibitor, shows durable disease clearance in ulcerative colitis, with more than 60 percent of patients maintaining remission through 4 years in the LUCENT-3 study.

Eli Lilly And Company | 06/05/2026 | By News Bureau |  190